Impact of carbon ion radiotherapy for primary spinal sarcoma

Keiji Matsumoto, Reiko Imai, Tadashi Kamada, Katsuya Maruyama, Hiroshi Tsuji, Hirohiko Tsujii, Yoshiyuki Shioyama, Hiroshi Honda, Kazuo Isu

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND Spinal sarcomas have been one of the most challenging diseases for orthopedic surgeons. The objective of this study was to retrospectively analyze carbon ion radiotherapy (CIRT) treatment results for spinal sarcoma. METHODS Forty-seven patients with 48 medically unresectable spinal sarcomas, excluding sacral tumors, received treatment with CIRT between 1996 and 2011. All patients were enrolled in phase 1/2 and phase 2 clinical trials of CIRT for bone and soft tissue sarcoma. The applied dose ranged from 52.8 gray equivalents (GyE) to 70.4 GyE (median, 64.0 GyE) in 16 fixed fractions over 4 weeks. RESULTS The median patient age was 54 years, and the cohort included 24 men and 23 women. Thirty-five patients were without prior treatment, and 12 patients had locally recurrent tumors after previous resection. The median follow-up was 25 months, and the median survival was 44 months (range, 5.2-148 months). The 5-year local control, overall survival, and progression free rates were 79%, 52%, and 48%, respectively. None of the 15 patients who had tumors measuring <100 cm3 had a local recurrence. No fatal toxicities occurred during follow-up. One patient each had a grade 3 late skin reaction and a grade 4 late skin reaction. Vertebral body compression was observed in 7 patients. One patient had a grade 3 late spinal cord reaction. Twenty-two of the surviving 28 patients who had primary tumors remained ambulatory without supportive devices. CONCLUSIONS CIRT appears to be both effective and safe for the treatment of patients with unresectable spinal sarcoma. Cancer 2013;119:3496-3503. © 2013 American Cancer Society. Carbon ion radiotherapy (CIRT) has advantages over conventional photon therapy in the treatment of sarcoma. The authors retrospectively analyze the results from CIRT for unresectable spinal sarcomas and demonstrate that CIRT is both effective and safe for the treatment of patients who have unresectable spinal sarcoma.

Original languageEnglish
Pages (from-to)3496-3503
Number of pages8
JournalCancer
Volume119
Issue number19
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Heavy Ion Radiotherapy
Sarcoma
Neoplasms
Therapeutics
Skin
Photons

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Matsumoto, K., Imai, R., Kamada, T., Maruyama, K., Tsuji, H., Tsujii, H., ... Isu, K. (2013). Impact of carbon ion radiotherapy for primary spinal sarcoma. Cancer, 119(19), 3496-3503. https://doi.org/10.1002/cncr.28177

Impact of carbon ion radiotherapy for primary spinal sarcoma. / Matsumoto, Keiji; Imai, Reiko; Kamada, Tadashi; Maruyama, Katsuya; Tsuji, Hiroshi; Tsujii, Hirohiko; Shioyama, Yoshiyuki; Honda, Hiroshi; Isu, Kazuo.

In: Cancer, Vol. 119, No. 19, 01.10.2013, p. 3496-3503.

Research output: Contribution to journalArticle

Matsumoto, K, Imai, R, Kamada, T, Maruyama, K, Tsuji, H, Tsujii, H, Shioyama, Y, Honda, H & Isu, K 2013, 'Impact of carbon ion radiotherapy for primary spinal sarcoma', Cancer, vol. 119, no. 19, pp. 3496-3503. https://doi.org/10.1002/cncr.28177
Matsumoto K, Imai R, Kamada T, Maruyama K, Tsuji H, Tsujii H et al. Impact of carbon ion radiotherapy for primary spinal sarcoma. Cancer. 2013 Oct 1;119(19):3496-3503. https://doi.org/10.1002/cncr.28177
Matsumoto, Keiji ; Imai, Reiko ; Kamada, Tadashi ; Maruyama, Katsuya ; Tsuji, Hiroshi ; Tsujii, Hirohiko ; Shioyama, Yoshiyuki ; Honda, Hiroshi ; Isu, Kazuo. / Impact of carbon ion radiotherapy for primary spinal sarcoma. In: Cancer. 2013 ; Vol. 119, No. 19. pp. 3496-3503.
@article{1722dac47dd64159bd80c1b9249f6cd0,
title = "Impact of carbon ion radiotherapy for primary spinal sarcoma",
abstract = "BACKGROUND Spinal sarcomas have been one of the most challenging diseases for orthopedic surgeons. The objective of this study was to retrospectively analyze carbon ion radiotherapy (CIRT) treatment results for spinal sarcoma. METHODS Forty-seven patients with 48 medically unresectable spinal sarcomas, excluding sacral tumors, received treatment with CIRT between 1996 and 2011. All patients were enrolled in phase 1/2 and phase 2 clinical trials of CIRT for bone and soft tissue sarcoma. The applied dose ranged from 52.8 gray equivalents (GyE) to 70.4 GyE (median, 64.0 GyE) in 16 fixed fractions over 4 weeks. RESULTS The median patient age was 54 years, and the cohort included 24 men and 23 women. Thirty-five patients were without prior treatment, and 12 patients had locally recurrent tumors after previous resection. The median follow-up was 25 months, and the median survival was 44 months (range, 5.2-148 months). The 5-year local control, overall survival, and progression free rates were 79{\%}, 52{\%}, and 48{\%}, respectively. None of the 15 patients who had tumors measuring <100 cm3 had a local recurrence. No fatal toxicities occurred during follow-up. One patient each had a grade 3 late skin reaction and a grade 4 late skin reaction. Vertebral body compression was observed in 7 patients. One patient had a grade 3 late spinal cord reaction. Twenty-two of the surviving 28 patients who had primary tumors remained ambulatory without supportive devices. CONCLUSIONS CIRT appears to be both effective and safe for the treatment of patients with unresectable spinal sarcoma. Cancer 2013;119:3496-3503. {\circledC} 2013 American Cancer Society. Carbon ion radiotherapy (CIRT) has advantages over conventional photon therapy in the treatment of sarcoma. The authors retrospectively analyze the results from CIRT for unresectable spinal sarcomas and demonstrate that CIRT is both effective and safe for the treatment of patients who have unresectable spinal sarcoma.",
author = "Keiji Matsumoto and Reiko Imai and Tadashi Kamada and Katsuya Maruyama and Hiroshi Tsuji and Hirohiko Tsujii and Yoshiyuki Shioyama and Hiroshi Honda and Kazuo Isu",
year = "2013",
month = "10",
day = "1",
doi = "10.1002/cncr.28177",
language = "English",
volume = "119",
pages = "3496--3503",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Impact of carbon ion radiotherapy for primary spinal sarcoma

AU - Matsumoto, Keiji

AU - Imai, Reiko

AU - Kamada, Tadashi

AU - Maruyama, Katsuya

AU - Tsuji, Hiroshi

AU - Tsujii, Hirohiko

AU - Shioyama, Yoshiyuki

AU - Honda, Hiroshi

AU - Isu, Kazuo

PY - 2013/10/1

Y1 - 2013/10/1

N2 - BACKGROUND Spinal sarcomas have been one of the most challenging diseases for orthopedic surgeons. The objective of this study was to retrospectively analyze carbon ion radiotherapy (CIRT) treatment results for spinal sarcoma. METHODS Forty-seven patients with 48 medically unresectable spinal sarcomas, excluding sacral tumors, received treatment with CIRT between 1996 and 2011. All patients were enrolled in phase 1/2 and phase 2 clinical trials of CIRT for bone and soft tissue sarcoma. The applied dose ranged from 52.8 gray equivalents (GyE) to 70.4 GyE (median, 64.0 GyE) in 16 fixed fractions over 4 weeks. RESULTS The median patient age was 54 years, and the cohort included 24 men and 23 women. Thirty-five patients were without prior treatment, and 12 patients had locally recurrent tumors after previous resection. The median follow-up was 25 months, and the median survival was 44 months (range, 5.2-148 months). The 5-year local control, overall survival, and progression free rates were 79%, 52%, and 48%, respectively. None of the 15 patients who had tumors measuring <100 cm3 had a local recurrence. No fatal toxicities occurred during follow-up. One patient each had a grade 3 late skin reaction and a grade 4 late skin reaction. Vertebral body compression was observed in 7 patients. One patient had a grade 3 late spinal cord reaction. Twenty-two of the surviving 28 patients who had primary tumors remained ambulatory without supportive devices. CONCLUSIONS CIRT appears to be both effective and safe for the treatment of patients with unresectable spinal sarcoma. Cancer 2013;119:3496-3503. © 2013 American Cancer Society. Carbon ion radiotherapy (CIRT) has advantages over conventional photon therapy in the treatment of sarcoma. The authors retrospectively analyze the results from CIRT for unresectable spinal sarcomas and demonstrate that CIRT is both effective and safe for the treatment of patients who have unresectable spinal sarcoma.

AB - BACKGROUND Spinal sarcomas have been one of the most challenging diseases for orthopedic surgeons. The objective of this study was to retrospectively analyze carbon ion radiotherapy (CIRT) treatment results for spinal sarcoma. METHODS Forty-seven patients with 48 medically unresectable spinal sarcomas, excluding sacral tumors, received treatment with CIRT between 1996 and 2011. All patients were enrolled in phase 1/2 and phase 2 clinical trials of CIRT for bone and soft tissue sarcoma. The applied dose ranged from 52.8 gray equivalents (GyE) to 70.4 GyE (median, 64.0 GyE) in 16 fixed fractions over 4 weeks. RESULTS The median patient age was 54 years, and the cohort included 24 men and 23 women. Thirty-five patients were without prior treatment, and 12 patients had locally recurrent tumors after previous resection. The median follow-up was 25 months, and the median survival was 44 months (range, 5.2-148 months). The 5-year local control, overall survival, and progression free rates were 79%, 52%, and 48%, respectively. None of the 15 patients who had tumors measuring <100 cm3 had a local recurrence. No fatal toxicities occurred during follow-up. One patient each had a grade 3 late skin reaction and a grade 4 late skin reaction. Vertebral body compression was observed in 7 patients. One patient had a grade 3 late spinal cord reaction. Twenty-two of the surviving 28 patients who had primary tumors remained ambulatory without supportive devices. CONCLUSIONS CIRT appears to be both effective and safe for the treatment of patients with unresectable spinal sarcoma. Cancer 2013;119:3496-3503. © 2013 American Cancer Society. Carbon ion radiotherapy (CIRT) has advantages over conventional photon therapy in the treatment of sarcoma. The authors retrospectively analyze the results from CIRT for unresectable spinal sarcomas and demonstrate that CIRT is both effective and safe for the treatment of patients who have unresectable spinal sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84884902261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884902261&partnerID=8YFLogxK

U2 - 10.1002/cncr.28177

DO - 10.1002/cncr.28177

M3 - Article

C2 - 23939877

AN - SCOPUS:84884902261

VL - 119

SP - 3496

EP - 3503

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -